Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood
暂无分享,去创建一个
K. Nathanson | J. Schiffman | G. Tomlinson | A. Erez | W. Kohlmann | J. Wasserman | K. Janeway | L. States | S. Voss | S. Rednam | H. Druker | J. Kamihara | A. Villani
[1] C. Larsson,et al. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention , 2017, JAMA oncology.
[2] K. Schneider,et al. Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient , 2017, Clinical Cancer Research.
[3] K. Pacak,et al. PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[4] P. Zhang,et al. Clinicopathological and Prognostic Analysis of Primary Gastrointestinal Stromal Tumor Presenting with Gastrointestinal Bleeding: a 10-Year Retrospective Study , 2017, Journal of Gastrointestinal Surgery.
[5] Antonio L Amelio,et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. , 2017, Cancer cell.
[6] W. Chung,et al. Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. Sluiter,et al. Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers , 2016, Familial Cancer.
[8] E. Budtz-Jørgensen,et al. Survival and causes of death in patients with von Hippel-Lindau disease , 2016, Journal of Medical Genetics.
[9] G. Pavesi,et al. Von Hippel-Lindau disease: an evaluation of natural history and functional disability. , 2016, Neuro-oncology.
[10] P. Meltzer,et al. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. , 2016, JAMA oncology.
[11] S. Richard,et al. Characterization of endolymphatic sac tumors and von Hippel–Lindau disease in the International Endolymphatic Sac Tumor Registry , 2016, Head & neck.
[12] E. Chew,et al. Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. , 2016, Journal of neurosurgery.
[13] T. Fojo,et al. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[14] K. Schaller,et al. Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. , 2015, CNS oncology.
[15] E. Budtz-Jørgensen,et al. Risk of new tumors in von Hippel–Lindau patients depends on age and genotype , 2015, Genetics in Medicine.
[16] R. Perera,et al. Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: Relevance to the diagnosis of neuroblastoma , 2015, Pediatric blood & cancer.
[17] L. Bortolotto,et al. Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation. , 2015, The Journal of clinical endocrinology and metabolism.
[18] E. Maher,et al. VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.
[19] S. Kirmani,et al. Hereditary paraganglioma-pheochromocytoma syndrome , 2018, Medicina Clínica (English Edition).
[20] T. Blundell,et al. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma , 2014, Human molecular genetics.
[21] A. Shaaban,et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families , 2014, Familial Cancer.
[22] Maria João M Bugalho,et al. Paragangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing , 2014, International journal of endocrinology.
[23] W. Linehan,et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. , 2014, Journal of neurosurgery.
[24] S. Gruber,et al. The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3). , 2014, The Journal of clinical endocrinology and metabolism.
[25] K. Pacak,et al. Clinical utility of chromogranin A in SDHx‐related paragangliomas , 2014, European journal of clinical investigation.
[26] P. Haentjens,et al. Gastrointestinal stromal tumor of the stomach: progresses in diagnosis and treatment. , 2013, Acta gastro-enterologica Belgica.
[27] M. Kosteljanetz,et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. , 2013, Danish medical journal.
[28] W. Foulkes,et al. Pheochromocytoma and paraganglioma syndromes: genetics and management update. , 2013, Current oncology.
[29] E. D. de Vries,et al. Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. , 2013, Endocrine-related cancer.
[30] J. Romijn,et al. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. , 2013, European journal of endocrinology.
[31] Laurence Amar,et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. , 2013, Cancer cell.
[32] U. Srirangalingam,et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non‐syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma , 2013, Clinical endocrinology.
[33] F. Beuschlein,et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma , 2013, Annals of clinical biochemistry.
[34] A. Villringer,et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma , 2013, Annals of clinical biochemistry.
[35] Electron Kebebew,et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.
[36] T. Cenci,et al. Von hippel-lindau disease and erythrocytosis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Kosteljanetz,et al. von Hippel-Lindau disease: Surveillance strategy for endolymphatic sac tumors , 2011, Genetics in Medicine.
[38] R. Lonser,et al. Management of von Hippel–Lindau disease-associated CNS lesions , 2011, Expert review of neurotherapeutics.
[39] J. Benítez,et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.
[40] N. Aaronson,et al. Compliance with periodic surveillance for Von-Hippel-Lindau disease , 2011, Genetics in Medicine.
[41] S. Richard,et al. von Hippel–Lindau disease: A clinical and scientific review , 2011, European Journal of Human Genetics.
[42] C. Vocke,et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. , 2011, The Journal of clinical endocrinology and metabolism.
[43] C. Cremers,et al. SDHAF2 (PGL2-SDH5) and Hereditary Head and Neck Paraganglioma , 2011, Clinical Cancer Research.
[44] W. Tormey,et al. Establishment of a paediatric age-related reference interval for the measurement of urinary total fractionated metanephrines , 2011, Annals of clinical biochemistry.
[45] S. Uhrig,et al. Pheochromocytoma in a 2.75‐year‐old‐girl with a germline von Hippel–Lindau mutation Q164R , 2010, American journal of medical genetics. Part A.
[46] A. V. D. van den Ouweland,et al. Genetic analysis of von Hippel‐Lindau disease , 2010, Human mutation.
[47] Patricia L. M. Dahia,et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.
[48] Fiona Douglas,et al. Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.
[49] W. Young,et al. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases , 2010, The American journal of surgical pathology.
[50] E. Budtz-Jørgensen,et al. Surveillance in von Hippel‐Lindau disease (vHL) , 2010, Clinical genetics.
[51] A. Vénisse,et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.
[52] P. Choyke,et al. Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease. , 2009, Clinical radiology.
[53] M. Meyerson,et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.
[54] E. Baudin,et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[55] S. Amir,et al. Hypoxia-inducible factor (HIF) in human tumorigenesis. , 2007, Histology and histopathology.
[56] Kentaro Takahashi,et al. [Von Hippel-Lindau disease]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[57] E. Korpershoek,et al. The Occurrence of SDHB Gene Mutations in Pheochromocytoma , 2006, Annals of the New York Academy of Sciences.
[58] W. Drake,et al. Benefits of Screening in von Hippel-Lindau Disease – Comparison of Morbidity Associated with Initial Tumours in Affected Parents and Children , 2006, Hormone Research in Paediatrics.
[59] K. Byth,et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.
[60] Eyal Gottlieb,et al. Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.
[61] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[62] National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents , 2004, Pediatrics.
[63] B. Rosner,et al. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents , 2004 .
[64] M. Walther,et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. , 2003, The Journal of clinical endocrinology and metabolism.
[65] S. Hunter,et al. Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma , 2011, Journal of Human Hypertension.
[66] R. B. van der Luijt,et al. Clinical management of Von Hippel-Lindau (VHL) disease. , 2001, The Netherlands journal of medicine.
[67] S. Libutti,et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. , 2000, Surgery.
[68] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[69] M. Ferguson-Smith,et al. Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.
[70] P. E. V. Hippel. Über eine sehr seltene Erkrankung der Netzhaut , 1904, Albrecht von Graefes Archiv für Ophthalmologie.
[71] S. Steinberg,et al. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma , 2017, Surgery.
[72] H. Mefford,et al. Hereditary Paraganglioma-Pheochromocytoma Syndromes -- GeneReviews® , 2016 .
[73] M. Kosteljanetz,et al. Von Hippel-Lindau disease (vHL) , 2013 .
[74] L. Sunde,et al. National clinical guideline for diagnosis and surveillance in Denmark 3 rd Edition , 2013 .
[75] H. Storr,et al. Pediatric endocrine screening for von Hippel-Lindau disease: benefits and the challenge of compliance. , 2011, Journal of Endocrinological Investigation.
[76] M. Caimarí,et al. Pheochromocytoma and Clear-Cell Renal Carcinoma in a Child with von Hippel-Lindau Disease: A Patient Report , 1999, Journal of Pediatric Endocrinology & Metabolism (JPEM).